Hepatocellular adenoma management and phenotypic classification: The Bordeaux experience

We took advantage of the reported genotype/phenotype classification to analyze our surgical series of hepatocellular adenoma (HCA). The series without specific known etiologies included 128 cases (116 women). The number of nodules varies from single, <5, and ≥5 in 78, 38, and 12 cases, respectively. The resection was complete in 95 cases. We identified 46 HNF1α‐inactivated HCAs (44 women), 63 inflammatory HCAs (IHCA, 53 women) of which nine were also β‐catenin–activated, and seven β‐catenin–activated HCAs (all women); six additional cases had no known phenotypic marker and six others could not be phenotypically analyzed. Twenty‐three of 128 HCAs showed bleeding. No differences were observed in solitary or multiple tumors in terms of hemorrhagic manifestations between groups. In contrast, differences were observed between the two main groups. Steatosis (tumor), microadenomas (resected specimen), and additional benign nodules were more frequently observed in HNF1α‐inactivated HCAs (P < 0.01) than in IHCAs. Body mass index > 25, peliosis (tumor), and steatosis in background liver were more frequent in IHCA (P < 0.01). After complete resection, new HCAs in the centimetric range were more frequently found during follow‐up (>1 year) in HNF1α‐inactivated HCA. After incomplete resection (HCA left in nonresected liver), the majority of HCA remained stable in the two main groups and even sometimes regressed. Six patients of 128 developed hepatocellular carcinoma (HCC) (all were β‐catenin–activated, whether inflammatory or not). Conclusion: There were noticeable clinical differences between HNF1α–inactivated HCA and IHCA; there was no increased risk of bleeding or HCC related to the number of HCAs; β‐catenin–activated HCAs are at higher risk of HCC. As a consequence, we believe that management of HCA needs to be adapted to the phenotype of these tumors. (HEPATOLOGY 2009.)

[1]  J. Zucman‐Rossi,et al.  Over‐expression of glutamine synthetase in focal nodular hyperplasia: a novel easy diagnostic tool in surgical pathology , 2009, Liver international : official journal of the International Association for the Study of the Liver.

[2]  S. Imbeaud,et al.  Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours , 2009, Nature.

[3]  J. Zucman‐Rossi,et al.  Hepatocellular adenomas: Magnetic resonance imaging features as a function of molecular pathological classification , 2008, Hepatology.

[4]  Sung-whan Cho,et al.  Surgical Management of Hepatocellular Adenoma: Take It or Leave It? , 2008, Annals of Surgical Oncology.

[5]  D. Gouma,et al.  Liver adenomatosis: re‐evaluation of aetiology and management , 2008, Liver international : official journal of the International Association for the Study of the Liver.

[6]  J. Zucman‐Rossi,et al.  Molecular pathogenesis of focal nodular hyperplasia and hepatocellular adenoma. , 2008, Journal of hepatology.

[7]  Cristel G. Thomas,et al.  Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry , 2007, Hepatology.

[8]  J. Zucman‐Rossi,et al.  Inflammatory syndrome with liver adenomatosis: the beneficial effects of surgical management , 2007, Gut.

[9]  S. Hussain,et al.  Case‐orientated approach to the management of hepatocellular adenoma , 2006, The British journal of surgery.

[10]  C. de Toma,et al.  Hepatocellular adenoma displaying a HNF1alpha inactivation in a patient with familial adenomatous polyposis coli. , 2006, Journal of hepatology.

[11]  J. Zucman‐Rossi,et al.  Genotype–phenotype correlation in hepatocellular adenoma: New classification and relationship with HCC , 2006, Hepatology.

[12]  L. Rubbia‐Brandt,et al.  Management of hepatocellular adenoma: solitary-uncomplicated, multiple and ruptured tumors. , 2005, World journal of gastroenterology.

[13]  L. Barthelmes,et al.  Liver cell adenoma and liver cell adenomatosis. , 2005, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[14]  J. Zucman‐Rossi,et al.  Clinical, morphologic, and molecular features defining so-called telangiectatic focal nodular hyperplasias of the liver. , 2005, Gastroenterology.

[15]  B. Alter,et al.  Androgens and liver tumors: Fanconi's anemia and non‐Fanconi's conditions , 2004, American journal of hematology.

[16]  B. le Bail,et al.  Obesity as a Risk Factor for Hepatocellular Carcinoma in a Noncirrhotic Patient , 2004, Seminars in liver disease.

[17]  V. Vilgrain,et al.  Association of multiple liver cell adenomas with spontaneous intrahepatic portohepatic shunt , 1994, Abdominal Imaging.

[18]  J. Zucman‐Rossi,et al.  Familial liver adenomatosis associated with hepatocyte nuclear factor 1alpha inactivation. , 2003, Gastroenterology.

[19]  S. Lepreux,et al.  Association of adenoma and focal nodular hyperplasia: experience of a single French academic center , 2003, Comparative hepatology.

[20]  O. Ciccarelli,et al.  Glycogenosis storage type I diseases and evolutive adenomatosis: an indication for liver transplantation , 2002, Transplant international : official journal of the European Society for Organ Transplantation.

[21]  G. Carrafiello,et al.  Rapid Disappearance of Hepatic Adenoma After Contraceptive Withdrawal , 2001, Journal of clinical gastroenterology.

[22]  B. le Bail,et al.  Multiple black hepatocellular adenomas in a male patient. , 2000, European journal of gastroenterology & hepatology.

[23]  G. Gores,et al.  Management of liver adenomatosis: results with a conservative surgical approach. , 1998, Liver transplantation and surgery : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[24]  C. Degott,et al.  Liver adenomatosis. An entity distinct from liver adenoma? , 1985, Gastroenterology.

[25]  J. Baum,et al.  Possible association between benign hepatomas and oral contraceptives. , 1973, Lancet.